A Lipoprotein Receptor Cluster IV Mutant Preferentially Binds Amyloid-β and Regulates Its Clearance from the Mouse Brain
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Soluble low density lipoprotein receptor-related protein-1 (sLRP1) binds ∼70% of amyloid β-peptide (Aβ) in human plasma. In Alzheimer disease (AD) and individuals with mild cognitive impairment converting to AD, plasma sLRP1 levels are reduced and sLRP1 is oxidized, which results in diminished Aβ peripheral binding and higher levels of free Aβ in plasma. Experimental studies have shown that free circulating Aβ re-enters the brain and that sLRP1 and/or its recombinant wild type cluster IV (WT-LRPIV) prevent Aβ from entering the brain. Treatment of Alzheimer APPsw +/0 mice with WT-LRPIV has been shown to reduce brain Aβ pathology. In addition to Aβ, LRPIV binds multiple ligands. To enhance LRPIV binding for Aβ relative to other LRP1 ligands, we generated a library of LRPIV-derived fragments and full-length LRPIV variants with glycine replacing aspartic acid residues 3394, 3556, and 3674 in the calcium binding sites. Compared with WT-LRPIV, a lead LRPIV-D3674G mutant had 1.6- and 2.7-fold higher binding affinity for Aβ40 and Aβ42 in vitro , respectively, and a lower binding affinity for other LRP1 ligands ( e.g. apolipoprotein E2, E3, and E4 (1.3–1.8-fold), tissue plasminogen activator (2.7-fold), matrix metalloproteinase-9 (4.1-fold), and Factor Xa (3.8-fold)). LRPIV-D3674G cleared mouse endogenous brain Aβ40 and Aβ42 25–27% better than WT-LRPIV. A 3-month subcutaneous treatment of APPsw +/0 mice with LRPIV-D3674G (40 μg/kg/day) reduced Aβ40 and Αβ42 levels in the hippocampus, cortex, and cerebrospinal fluid by 60–80% and improved cerebral blood flow responses and hippocampal function at 9 months of age. Thus, LRPIV-D3674G is an efficient new Aβ clearance therapy. Background: Wild type LRP1 cluster IV (WT-LRPIV) binds plasma Aβ and reduces Aβ-related pathology in APPsw +/0 mice. Results: A novel LRPIV-D3674G mutant binds Aβ with a higher affinity than WT-LRPIV and clears brain Aβ better than WT-LRPIV. LRPIV-D3674G reduces effectively Aβ pathology in APPsw +/0 mice. Conclusion: LRPIV-D3674G is an efficient Aβ clearance agent. Significance: Aβ clearance therapy is critical for treatment of Alzheimer disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“A concentration in brain interstitial fluid is controlled by its rate of production in brain; influx and/or re-entry of circulating, peripheral A into the brain across the blood-brain barrier (BBB) via receptor for advanced glycation end products (RAGE) (4); and clearance of A from the brain (5, 6).”
BackgroundThe toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 1×
“Therefore, LRPIV-D3674G could be developed as a potential therapeutic agent administered as a monotherapy and/or in combination with other A -lowering agents, such as Notch-sparing -secretase inhibitors or -secretase (BACE1) inhibitors (57, 69, 70) to restore the natural peripheral sinkmechanism for A inMCI andADpatie…”
BackgroundRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“Several A antibody therapies are directed at facilitating A clearance from the brain (25, 26).”
BackgroundLRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Self-citationKayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., Margol, L., Wu, J., Breydo, L., Thompson, J. L., et al. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-18 · Cited by 773
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771
Self-citationBell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670
Self-citationDeane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58642 · Cited by 619 · cited 1×
“Microglia—Formaldehyde fixed brain sections were used for immunostaining of the microglia marker Iba-1 (ionized calcium-binding adaptor molecule 1), as described (47).”
MethodSelf-citationDeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563
RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519
Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy
Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511
ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration
Zhong, Z., Deane, R., Ali, Z., Parisi, M., Shapovalov, Y., O'Banion, M. K., Stojanovic, K., Sagare, A., Boillee, S., Cleveland, D. W., et al. (2008) · Nature Neuroscience · doi:10.1038/nn2073 · Cited by 476 · cited 1×
“Prussian Blue Staining—Briefly, acetone-fixed saggital brain sections from vehicle-treated and LRPIV-D3674-treated mice were incubated in a 5% potassium ferrocyanide and 5% hydrochloric acid solution (1:1 working solution) for 30 min, as reported (48).”
MethodSelf-citationWahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., Kowalewski, T., & Holtzman, D. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407963200 · Cited by 474
Sehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., Khanna, P., Jain, S. C., Thakur, S. S., & Ravindranath, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112209109 · Cited by 390
Proteolytic Degradation of Amyloid -Protein
Saido, T., & Leissring, M. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006379 · Cited by 368 · cited 1×
“A is cleared from the brain by different mechanisms, including transport across the BBB via low density lipoprotein receptor-related protein-1 (LRP1) (5, 7–9) and enzymatic degradation in the brain (10).”
BackgroundBlood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model
UJIIE, M., DICKSTEIN, D. L., CARLOW, D. A., & JEFFERIES, W. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800212 · Cited by 351
Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease
Wu, Z., Guo, H., Chow, N., Sallstrom, J., Bell, R. D., Deane, R., Brooks, A. I., Kanagala, S., Rubio, A., Sagare, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1287 · Cited by 280
Self-citationSRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells
Bell, R. D., Deane, R., Chow, N., Long, X., Sagare, A., Singh, I., Streb, J. W., Guo, H., Rubio, A., Van Nostrand, W., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1819 · Cited by 261 · cited 1×
“Down-regulation of LRP1 at the BBB due to vascular risk factors and/or oxidative stress (17, 64), oxidation, or reduced levels of sLRP1 in plasma (14) and reduced expression of LRP1 in the liver (65) lead to accumulation of A in brain in different experimental models.”
BackgroundSelf-citationZlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261 · cited 2×
“A concentration in brain interstitial fluid is controlled by its rate of production in brain; influx and/or re-entry of circulating, peripheral A into the brain across the blood-brain barrier (BBB) via receptor for advanced glycation end products (RAGE) (4); and clearance of A from the brain (5, 6).”
BackgroundSelf-citationBritschgi, M., Olin, C. E., Johns, H. T., Takeda-Uchimura, Y., LeMieux, M. C., Rufibach, K., Rajadas, J., Zhang, H., Tomooka, B., Robinson, W. H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904866106 · Cited by 201 · cited 1×
“Circulating endogenousA antibodies that bind a fraction of A in plasma (14, 22, 53–56) are also decreased in early stages of AD (22, 57, 58), further emphasizing the need for peripheral A binding treatments.”
BackgroundTamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., & Terasaki, T. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0208-7 · Cited by 119
Cited by
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589
Self-citationRetractedNeurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559
Self-citationRole of Blood-Brain Barrier in Alzheimer’s Disease
Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180098 · Cited by 370
Shinohara, M., Tachibana, M., Kanekiyo, T., & Bu, G. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075796 · Cited by 297
“The resulting intracellular domain of LRP1 serves as a transcription regulator, affecting expression of several genes, including interferon-, similar to amyloid precursor protein (APP) (28–31), while secreted soluble forms of LRP1 (sLRP1) can affect A metabolism (32, 33) as discussed later.”
BackgroundKanekiyo, T., & Bu, G. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00093 · Cited by 281
“When recombinant soluble LRP1 domain IV (LRPIV) or LRPIV-D3674G mutant were administrated intraperitoneally into amyloid model mice for 3 months, brain Aβ levels were significantly decreased (Sagare et al., 2007, 2013a).”
BackgroundMethodInfluential
Metadata
- Authors
- Sagare, A. P., Bell, R. D., Srivastava, A., Sengillo, J. D., Singh, I., Nishida, Y., Chow, N., & Zlokovic, B. V.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 288
- Issue
- 21
- Pages
- 15154-15166
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1985720189
- Cited by
- 40
- References
- 24
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.